2022
PHARMAC undertakes a review on funding for Dexcom G6 CGM technology
With our longstanding support for New Zealanders living with Type 1 diabetes, we are extremely pleased to share that PHARMAC is undertaking a review on CGM funding, following a recommendation by the PTAC Diabetes Subcommittee that the Dexcom G6 CGM system be listed on the Pharmaceutical Schedule with high priority. This review acknowledges the value …
Continue reading "PHARMAC undertakes a review on funding for Dexcom G6 CGM technology"
17.02.2022